Company profile
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ: TELO · Healthcare · Biotechnology
PublicHQ Baltimore, FLCIK 0001971532Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 48DQ —GM —SS 34
v0.1 · 35/100 weight · pillars only
↑ Altman-Z, balance-sheet leverage · ↓ workforce scale, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$10.4M
Employees
2
as of 2026-08-20
Market cap
$80.5M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$10.4M-$10.4M2025
Total assets$7.3M$7.3M2025
Liabilities$1.4M$1.4M2025
Equity$5.9M$5.9M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Telomir Pharmaceuticals, Inc. Common Stock’s financial profile?
Telomir Pharmaceuticals, Inc. Common Stock earned -$10.4M in FY2025 net income.
Peers · Healthcare
Oncolytics Biotech Inc.——Adicet Bio, Inc.——Dogwood Therapeutics, Inc.——RetinalGenix Technologies Inc.——Cingulate Inc.——Instinct Bio Technical Co. Holdings Inc.——Key facts
CEOErez Aminov
SectorHealthcare
IndustryBiotechnology
HeadquartersBaltimore, FL
ExchangeNASDAQ: TELO
Employees2
IPO date2019-04-09
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.